0000899243-23-015673.txt : 20230615
0000899243-23-015673.hdr.sgml : 20230615
20230615213854
ACCESSION NUMBER: 0000899243-23-015673
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230613
FILED AS OF DATE: 20230615
DATE AS OF CHANGE: 20230615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheng Andrew
CENTRAL INDEX KEY: 0001778307
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 231019218
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY, 3RD FLOOR
STREET 2: C/O AKERO THERAPEUTICS, INC.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-13
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001778307
Cheng Andrew
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President & CEO
1
Common Stock
2023-06-13
4
S
0
1613
55.16
D
407680
D
The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the reporting person. The sales reported on this Form 4 represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. Such sales were automatic and intended to qualify under Rule 10b5-1.
/s/ Jonathan Young, Attorney-in-Fact
2023-06-15